Dr Reddy's launches Redotil

Dr Reddy's Laboratories has launched Redotil (racecadotril), the first anti-hypersecretory agent for the management of acute diarrhea in India. The product will be available as 100 mg capsules.

Commenting on the launch, Jaspal Singh Bajwa, president (branded formulations business), Dr. Reddy's, said: "Redotil addresses a critical need of the medical fraternity across the country. Redotil's unique mechanism of action and quick control of diarrhea makes it a novel drug in this therapeutic category."

Racecadotril is the first of a new class of anti-diarrhoeal agents (an enkephalinase inhibitor) with a highly specific anti-secretory action. It works through a novel mechanism of action by inhibiting the action of enkephalinase, which causes hypersecretion, and producing an antidiarrheal effect.

The plain anti-diarrheal market in India is estimated to be about Rs 46 crore with a growth of four per cent every year. Diarrhea is one of the leading causes of morbidity and mortality in infants and children worldwide. About one million diarrhea-related deaths occur each year in South East Asia.